Amit Kumar Purchases 5,000 Shares of Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar acquired 5,000 shares of the company’s stock in a transaction dated Monday, July 20th. The shares were bought at an average cost of $3.46 per share, with a total value of $17,300.00. Following the completion of the acquisition, the chief executive officer directly owned 640,812 shares in the company, valued at $2,217,209.52. The trade was a 0.79% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Amit Kumar also recently made the following trade(s):

• On Friday, July 24th, Amit Kumar bought 3,000 shares of Anixa Biosciences stock. The stock was bought at an average price of $3.73 per share, with a total value of $11,190.00.
• On Monday, July 27th, Amit Kumar bought 3,188 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $3.37 per share, for a total transaction of $10,743.56.
• On Monday, July 27th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.44 per share, for a total transaction of $17,200.00.
• On Friday, July 10th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $3.04 per share, with a total value of $15,200.00.
• On Friday, June 12th, Amit Kumar acquired 21,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $2.50 per share, with a total value of $52,500.00.

Anixa Biosciences Trading Down 1.1%

Shares of Anixa Biosciences stock opened at $3.48 on Thursday. The firm has a market capitalization of $118.39 million, a PE ratio of -11.23 and a beta of 0.59. The business’s 50-day moving average price is $2.94 and its 200-day moving average price is $2.92. Anixa Biosciences Inc has a 12 month low of $2.32 and a 12 month high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. As a group, analysts predict that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Anixa Biosciences

Several hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC purchased a new stake in Anixa Biosciences in the fourth quarter worth $83,000. Graham Capital Management L.P. purchased a new position in Anixa Biosciences during the 4th quarter valued at $81,000. CIBC Bancorp USA Inc. purchased a new position in Anixa Biosciences during the 3rd quarter valued at $51,000. Marshall Wace LLP bought a new position in Anixa Biosciences in the 2nd quarter worth $39,000. Finally, Millennium Management LLC bought a new position in Anixa Biosciences in the 4th quarter worth $38,000. 29.13% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ANIX has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Anixa Biosciences in a research note on Wednesday, June 17th. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Zacks Research upgraded shares of Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Anixa Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.